tirzepatide for ckd Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist | Clinical Pharmacokinetics Tirzepatide Prescribing Practices and Efficacy

SURPASS-4, a cardiovascular safety study in 2,002 patients with type 2 diabetes and increased cardiovascular risk, demonstrated blood pressure changes over 104 weeks

Ianalumabs Phase III trials showed a significant reduction in disease activity with a favorable safety profile, and an approval is likely in 2026

I recommend to my mom and will continue for another month Made the process very simple and quick

For the study, researchers looked at the health data of 41,222 adults who were overweight or obese and had been prescribed one of the two drugs for the first time

Eli Lilly markets the only FDA-approved GIP/GLP-1 dual agonist (tirzepatide) and has a GLP-1-selective option as well (dulaglutide)

Heart Rate: One specific thing we noticed in Retatrutide trials is a slight increase in heart rate for some people